2023 2023 Nucleosides, Nucleotides and Oligonucleotides GRC & GRS

2023 2023 核苷、核苷酸和寡核苷酸 GRC

• 批准号: 10609239
• 负责人: Katherine L Seley-Radtke
• 金额: $ 0.7万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-10 至 2023-07-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10609239
• 关键词: 2019-nCoV; Acute; Address; African American; Antibiotics; Antiviral Agents; Attitude; Basic Science; Biology; Biomedical Research; COVID-19 pandemic; Calibration; Chemicals; Chemistry; Clinic; Collaborations; Communicable Diseases; Communities; Coronavirus; Creativeness; Dedications; Development; Diagnostic; Disease; Effectiveness; Employment Opportunities; Environment; Ethnic Origin; Ethnic Population; Fees; Female; Funding; Funding Agency; Future; Gender; Genetic Diseases; Goals; Government; HIV/AIDS; Health; Hepatitis C; Hour; Human; Human Biology; Industrialization; Industry; Institution; International; Knowledge; Learning; Light; Marketing; Mentors; Minority; Nucleic Acids; Nucleosides; Nucleotides; Occupations; Oligonucleotides; Oral; Organizational Objectives; Participant; Pharmaceutical Preparations; Postdoctoral Fellow; Purine Nucleosides; RNA; Recording of previous events; Research; Research Personnel; Science; Scientist; Spinal Muscular Atrophy; Structural Chemistry; Students; Tenofovir; Therapeutic; Underrepresented Minority; Underrepresented Populations; Woman; Zidovudine; career; clinical application; clinical translation; coronavirus therapeutics; current pandemic; drug development; drug discovery; effective therapy; epitranscriptome; improved; insight; interest; meetings; member; men; new technology; nucleic acid-based therapeutics; posters; programs; recruit; remdesivir; small molecule; social group; success; symposium; tool; undergraduate student; vaccine development

PROJECT SUMMARY/ABSTRACT This proposal seeks funding to support the 2023 Nucleosides, Nucleotides and Oligonucleotides (NNO) Gordon Research Conference and associated Gordon Research Seminar. This will be the 21st edition of this conference, which was initiated in 1976. Throughout its history, this conference has addressed topics that are directly related to the fundamental science of human biology and the treatment of disease. Nucleosides and nucleotides have been extremely effective drugs, most notably antivirals such as AZT and Harvoni, for the treatment of HIV/AIDS and hepatitis C, respectively. Meanwhile, the field has broadened to include oligonucleotides as biomedical research tools and, increasingly, therapeutics for genetic diseases, such as Spinraza, which treats spinal muscular atrophy. There are four specific aims for the conference: (1) facilitate scientists in the field to learn about the latest advances in academic, industrial and government research labs; (2) introduce new scientists to the topic; (3) provide networking opportunities to build relationships and collaborations as well as matching students with potential future employers; (4) enhance the diversity of our field by providing speaking and discussion leader opportunities to women and members of under-represented ethnic groups. These specific aims will contribute to long-term goal of the conference, which is to have a broad and sustainable impact on both basic science and clinical translation of nucleosides, nucleotides and oligonucleotides in order to improve human health. The 2023 edition of the conference will include sessions dedicated to (1) emerging therapeutics for coronaviruses, (2) small molecules - chemistry & applications, (3) chemical biology and nucleic acid based diagnostics, (4) oligonucleotide and nucleic acid therapeutics, (5) structural chemistry of nucleic acids, and (6) RNA-targeting and epitranscriptomes. (Other sessions will be organized after final invitations have been accepted and speakers have submitted their titles.) The PI solicited nominations from experts in the field, emphasizing the desire to identify members of under-represented groups and young scientists as potential speakers. Of the 31 invited speakers, 15 are women, including three African-American females; the average GRC has 30% female speakers. In addition, currently we have six speakers from underrepresented minorties. The affiliated Gordon Research Seminar will feature oral presentations by students and postdocs, a panel discussion with established scientists in the field, and the opportunity to create a sense of community prior to the start of the GRC. In addition, the GRC “Power Hour” will take place during one afternoon and provides a forum in which all participants can discuss the unique challenges faced by women in science. Thus, while the cutting edge science described during the oral sessions will undoubtedly inspire others to move their own research forward in new and creative ways, the GRS, Power Hour and other efforts to support women, minorities and young scientists in general will strengthen the field and its impact on human health for decades to come.

项目总结/摘要 该提案寻求资金支持2023年核苷，核苷酸和寡核苷酸（NNO）戈登 研究会议和相关的戈登研究研讨会。这将是第21届会议， 这是在1976年开始的。纵观其历史，本次会议所讨论的主题直接相关 人类生物学和疾病治疗的基础科学。核苷和核苷酸具有 这些药物是治疗艾滋病毒/艾滋病极为有效的药物，最著名的是抗病毒药物，如AZT和Harvoni， 和丙型肝炎。与此同时，该领域已经扩大到包括寡核苷酸作为生物医学 研究工具和越来越多的遗传疾病治疗方法，如Spinraza，治疗脊柱疾病， 肌肉萎缩。 会议有四个具体目标：（1）促进该领域的科学家了解最新的 学术、工业和政府研究实验室的进步;（2）介绍新的科学家;（3） 提供网络机会，建立关系和合作，以及匹配学生与 潜在的未来雇主;（4）通过提供演讲和讨论领袖来增强我们领域的多样性 为妇女和代表性不足的族裔群体成员提供机会。这些具体目标将有助于 会议的长期目标是对基础科学和 核苷、核苷酸和寡核苷酸的临床翻译，以改善人类健康。 2023年版的会议将包括专门讨论以下问题的会议：（1） 冠状病毒，（2）小分子-化学和应用，（3）化学生物学和核酸基 诊断学，（4）寡核苷酸和核酸治疗学，（5）核酸的结构化学，和（6） RNA靶向和表转录组。（其他会议将在收到最后邀请后举行。 已接受，发言者已提交其标题。PI征求了该领域专家的提名， 强调希望确定代表性不足的群体和年轻科学家的成员作为潜力， 扬声器.在31位受邀演讲者中，15位是女性，其中包括3位非洲裔美国女性; GRC有30%的女性发言者。此外，目前我们有六名发言者来自代表性不足的少数群体。 附属的戈登研究研讨会将以学生和博士后的口头报告为特色， 与该领域的知名科学家进行讨论，并有机会在 GRC的开始。此外，GRC“Power Hour”将在一个下午举行，并提供一个论坛 所有与会者都可以讨论妇女在科学领域面临的独特挑战。当切割 在口头会议中描述的边缘科学无疑会激励其他人推动他们自己的研究 以新的和创造性的方式推进GRS，Power Hour和其他支持妇女，少数民族和 青年科学家将在未来几十年加强该领域及其对人类健康的影响。